Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy

Background. The main attention regarding prognostic and predictive markers in NSCLC directs towards the EGFR-targeted pathway, where the most studied genetic alterations include EGFR mutations, EGFR copy number, and KRAS mutations. We wanted to explore the prognostic impact of mutated KRAS in the st...

Descripción completa

Detalles Bibliográficos
Autores principales: Hallqvist, A., Enlund, F., Andersson, C., Sjögren, H., Hussein, A., Holmberg, E., Nyman, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4437400/
https://www.ncbi.nlm.nih.gov/pubmed/26316935
http://dx.doi.org/10.1155/2012/587424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4437400/
https://www.ncbi.nlm.nih.gov/pubmed/26316935
http://dx.doi.org/10.1155/2012/587424

Ejemplares similares